Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab deruxtecan in HER2-overexpressing or mutated NSCLC
NCT03505710Phase 2Terminated
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2018
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of trastuzumab deruxtecan in non-small cell lung cancer (NSCLC) (3 cohorts), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Objective Response Rate by Independent Central Review up to 36 months. Started May 2018; status: terminated.
02
Drugs
trastuzumab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03505710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03505710.